9 chapters, 350+ pages, 178 exhibits, 750+ endnotes: There is nothing else available that comes close to this valuable resource.
We are providing you with the opportunity to preorder this thoroughly updated, revised, and expanded 2024-25 edition at special discounted prices. This means that you can be among the first to access our new report. Those who preorder will receive a download link before October 8.
- Download a free pre-publication report overview (including key industry trends, What's New in this edition, the Table of Contents, and a List of Exhibits)
Special preorder and launch pricing discounts will be valid through October 23, 2024.
Read on for more details.
The 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors remains the most comprehensive, fact-based tool for understanding and analyzing the large and growing U.S. pharmaceutical distribution industry. This unique, encyclopedic resource is your ultimate guide to wholesale distribution’s role in the complex web of interactions within U.S. prescription drug channels.
Our 2024-25 edition contains the most current financial and industry data. As always, we have updated all market and industry data with the most current information available. The report also updates our annual analyses of the strategies, market positions, and executive compensation of the three largest companies: Cencora, Cardinal Health, and McKesson.
We review each wholesaler’s business segments and underlying business profitability, based upon our proprietary economic models. This information allows you to assess differences among the public wholesalers’ business organizations, strategies, and financial performance. Where appropriate, financial data have been restated based on updated disclosures.
The notable new material in this 2024-25 edition includes new data on physician and hospital markets, new material on the impact of a reduction in brand-name list prices on wholesalers’ buy-side payments from manufacturers, a new section examining the impact of direct-to-pharmacy models and direct-to-patient channels, and updated and expanded analyses of the Inflation Reduction Act’s likely consequences for wholesalers. See pages 9 and 10 of the free report overview for more details on the new sections and content.
Thank you for your interest in our work. If you have any questions before purchasing a license to the report, please email me (afein@drugchannels.net). Enjoy!
P.S. I hope you enjoy the report's nifty new cover, courtesy of our friends at HMP Global.
No comments:
Post a Comment